Portal hypertension is an important, if not the most important, factor affecting the clinical course of patients with cirrhosis, as it can predict the development of cirrhosis-related complications, such as variceal bleeding, ascites, and hepatic encephalopathy [1‐3]. The management of portal hypertension should cover early screening and detection, primary prevention of complications, emergency care for variceal bleeding, and secondary prevention. Here, we propose a concept termed “A Community of Portal Hypertension” (Fig. 1), emphasizing multidisciplinary team (MDT)-oriented practice, innovation-oriented research, and patient-oriented care, to promote comprehensive management of portal hypertension.
WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.